Fmoc-6-caproic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: Fmoc-6-caproic acid
• 英文别名: 7-(9H-fluoren-9-ylmethoxy)-7-oxoheptanoic acid
• 化学式: C₂₁H₂₂O₄
• 分子量: 338.403
• InChiKey: BUXDACQHZOTTQO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  25
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Fmoc-6-caproic acid 、 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 以6.7 g的产率得到
  参考文献：
  名称：

  [EN] BICYCLIC HETEROCYCLES AND THEIR LIGANDS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS
  [FR] HÉTÉROCYCLES BICYCLIQUES ET LEURS LIGANDS POUR L'ADMINISTRATION CIBLÉE D'AGENTS THÉRAPEUTIQUES

  摘要：

  the present invention provides novel bicyclic heterocycles and their targeting ligands which can conjugate to a therapeutic agent, for use as medicament. The preparation method thereof, pharmaceutical compositions comprising the therapeutic compounds, and the pharmaceutical uses are disclosed.

  公开号：

  WO2023179773A1

文献信息

• Novel Dual-Use Peptidase Inhibitors as Prodrugs for a Therapy of Inflammatory and Other Diseases
  申请人：Ansorge Siegfried

  公开号：US20090124667A1

  公开（公告）日：2009-05-14

  Compounds of the general formulae (1) and (2) A-B-D-B′-A′  (1) and A-B-D-E  (2) in which A and A′ may be identical or different and are the residue in which X is S, O, CH 2 , CH 2 CH 2 , CH 2 O or CH 2 NH, and Y is H or CN, and * designates a chiral carbon atom preferably in S- or L-configuration; B and B′ may be identical or different and are an O, N or S containing or non-containing, unsubstituted or substituted, unbranched or branched alkylene residue, cycloalkylene residue, aralkylene residue, heterocycloalkylene residue, heteroarylalkylene residue, arylamidoalkylene residue, heteroarylamidoalkylene residue, unsubstituted or mono- or poly-substituted arylene residue or heteroarylene residue having one or more five-, six- or seven-membered ring(s); D is —S—S— or —Se—Se—; and E is the group —CH 2 —CH(NH 2 )—R 9 or —CH 2 —*CH(NH 2 )—R 9 respectively in which R 9 is an O, N or S containing or non-containing, unsubstituted or substituted, unbranched or branched alkyl residue, cycloalkyl residue, aralkyl residue, heterocycloalkyl residue, heteroarylalkyl residue, arylamidoalkyl residue, heteroarylamidoalkyl residue, unsubstituted or mono- or poly-substituted aryl residue or heteroaryl residue having one or more five-, six- or seven-membered ring(s) and * designates a chiral carbon atom preferably in the S- or L-configuration; or the acid addition salts thereof with organic and/or inorganic acids; as well as to the use of the compounds of the general formulae (1) and (2) in medicine.

  通式（1）和（2）中的化合物为A-B-D-B′-A′（1）和A-B-D-E（2），其中A和A′可以相同也可以不同，是残基，其中X为S、O、CH2、 、 O或 NH，Y为H或CN，*代表一个手性碳原子，最好是S-或L-构型；B和B′可以相同也可以不同，是含有或不含有O、N或S，未取代或取代，直链或支链的烷基残基，环烷基残基，芳基烷基残基，杂环烷基残基，杂芳烷基残基，芳基酰胺烷基残基，杂芳基酰胺烷基残基，未取代或单取代或多取代的芳基残基或杂芳基残基，具有一个或多个五、六或七元环的；D为—S—S—或—Se—Se—；E为基团— —CH（NH2）—R9或— —*CH（NH2）—R9，其中R9为含有或不含有O、N或S，未取代或取代，直链或支链的烷基残基，环烷基残基，芳基烷基残基，杂环烷基残基，杂芳烷基残基，芳基酰胺烷基残基，杂芳基酰胺烷基残基，未取代或单取代或多取代的芳基残基或杂芳基残基，具有一个或多个五、六或七元环，*代表一个手性碳原子，最好是S-或L-构型；或其与有机和/或无机酸的酸盐；以及通式（1）和（2）中的化合物在医学上的应用。
• Size-Controlled Formation of Noble-Metal Nanoparticles in Aqueous Solution with a Thiol-Free Tripeptide
  作者：Stefano Corra、Urszula Lewandowska、Edmondo M. Benetti、Helma Wennemers

  DOI：10.1002/anie.201510337

  日期：2016.7.18

  the size‐controlled formation of other noble‐metal nanoparticles (Pt and Au). Studies with close analogues of peptide 1 revealed a specific role of each of the three amino acids for the formation and stabilization of the nanoparticles. These data combined with microscopic and spectroscopic analyses provided insight into the structure of the self‐assembled peptidic monolayer around the metal core. The

  甲组合筛选揭示了肽H-的His- d -Leu- d -Asp-NH 2（1）作为用于与为3nm平均直径和超过9个月的稳定性单分散的，水溶性的钯纳米粒子的生成的添加剂。三肽也被证明也可用于其他贵金属纳米粒子（Pt和Au）的尺寸控制形成。用肽1的紧密类似物进行研究揭示了三种氨基酸中的每一种对于纳米颗粒的形成和稳定化的特定作用。这些数据与显微镜和光谱分析相结合，提供了对围绕金属核的自组装肽单层结构的见解。该结果为功能化金属纳米颗粒的开发打开了有趣的前景。
• LIPID-PEPTIDE-POLYMER CONJUGATES AND NANOPARTICLES THEREOF
  申请人：The Regents of the University of California

  公开号：EP2545072A2

  公开（公告）日：2013-01-16
• Lipid-Peptide-Polymer Conjugates and Nanoparticles Thereof
  申请人：Xu Ting

  公开号：US20130121917A1

  公开（公告）日：2013-05-16

  The present invention provides a conjugate having a peptide with from about 10 to about 100 amino acids, wherein the peptide adopts a helical structure. The conjugate also includes a first polymer covalently linked to the peptide, and a hydrophobic moiety covalently linked to the N-terminus of the peptide, wherein the hydrophobic moiety comprises a second polymer or a lipid moiety. The present invention also provides helix bundles form by self-assembling the conjugates, and particles formed by self-assembling the helix bundles. Methods of preparing the helix bundles and particles are also provided.
• US8470855B2
  申请人：——

  公开号：US8470855B2

  公开（公告）日：2013-06-25